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Abstract
Background
Chronic kidney disease (CKD) is strongly associated with coronary artery disease (CAD).
We established a prospective observational nationwide multicenter registry to evaluate cur-
rent treatment and outcomes in patients with both CKD and angiographically documented
CAD.
Methods
In 32 cardiological centers 3,352 CAD patients with50% stenosis in at least one coronary
artery were enrolled and classified according to their estimated glomerular filtration rate and
proteinuria into one of five stages of CKD or as a control group.
Results
2,723 (81.2%) consecutively enrolled patients suffered fromCKD. Compared to controls,
CKD patients had a higher prevalence of diabetes, hypertension, peripheral artery diseases,
heart failure, and valvular heart disease (each p<0.001). Myocardial infarctions (p = 0.02), cor-
onary bypass grafting, valve replacements and pacemaker implantations had been recorded
more frequently (each p<0.001). With advanced CKD, the number of diseased coronary ves-
sels and the proportion of patients with reduced left ventricular ejection fraction (LVEF)
increased significantly (both p<0.001). Percutaneous coronary interventions were performed
PLOSONE | DOI:10.1371/journal.pone.0148057 February 9, 2016 1 / 16
OPEN ACCESS
Citation: Reinecke H, Breithardt G, Engelbertz C,
Schmieder RE, Fobker M, Pinnschmidt HO, et al.
(2016) Baseline Characteristics and Prescription
Patterns of Standard Drugs in Patients with
Angiographically Determined Coronary Artery
Disease and Renal Failure (CAD-REF Registry).
PLoS ONE 11(2): e0148057. doi:10.1371/journal.
pone.0148057
Editor: Heye Zhang, Shenzhen Institutes of
Advanced Technology, CHINA
Received: July 2, 2015
Accepted: December 3, 2015
Published: February 9, 2016
Copyright: © 2016 Reinecke et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: To replicate the
findings of our study all data is found within our
manuscript. Additional data that is a part of the CAD-
REF registry are available upon request to the
investigators (Eva Brand, Holger Reinecke) and after
approval from the Ethik-Kommission der
Ärztekammer Westfalen-Lippe und der Westfälischen
Wilhelms-Universität Münster, Institutional Review
Board. Interested researchers may submit requests
for access of data to ethik-kommission@aekwl.de,
less frequently (p<0.001) while coronary bypass grafting was recommendedmore often (p =
0.04) with advanced CKD.With regard to standard drugs in CAD treatment, prescriptions
were higher in our registry than in previous reports, but beta-blockers (p = 0.008), and angio-
tensin-converting-enzyme inhibitors and/or angiotensin-receptor blockers (p<0.001) were
given less often in higher CKD stages. In contrast, in the subgroup of patients with moderately
to severely reduced LVEF the prescription rates did not differ between CKD stages. In-hospi-
tal mortality increased stepwise with each CKD stage (p = 0.02).
Conclusions
In line with other studies comprising CKD cohorts, patients’morbidity and in-hospital mortal-
ity increased with the degree of renal impairment. Although cardiologists’ drug prescription
rates in CAD-REF were higher than in previous studies, they were still lower especially in
advanced CKD stages compared to cohorts treated by nephrologists.
Introduction
Chronic kidney disease (CKD) belongs to the fastest growing and globally occurring health
burdens, affecting patients at any age and across ethnic groups [1,2]. CKD determined by
decreased glomerular filtration rate (GFR) or isolated proteinuria is strongly associated with
severe cardiovascular diseases [3–5] such as coronary artery disease (CAD), myocardial infarc-
tion (MI), congestive heart failure, stroke, and atrial fibrillation [4,6–10]. Apart from multiple
unfavorable pathophysiological causes leading to the increased morbidity and mortality in
CKD in general [11,12], non-adherence in terms of standard guideline therapies, such as drugs
prescriptions, and interventional measures is one additional cause for the deleterious outcome
of CKD patients [13–15]. Therefore, current guidelines highlight the importance of consequent
treatment especially by standard drugs [16].
Despite a vast knowledge of development and progression of CKD and CAD [11,12] indi-
vidual risk stratification and new successful treatment strategies in CKD patients are still miss-
ing [17]. Therefore, a few recent studies have been established which aimed to identify new risk
factors and biomarkers as well as differences in the current treatment of CKD patients contrib-
uting to their deleterious prognosis [17–21]. Here we report on the baseline characteristics and
in-hospital outcomes of the Coronary Artery Disease and Renal Failure (CAD-REF) Registry
[21] including 3,352 German patients with angiographically documented CAD and different
stages of CKD including CAD patients with normal renal function as control subjects. With
regard to the elsewhere reported therapeutic nihilism or so-called inertia [13–15] we also
focused on drug prescriptions at enrollment and discharge in different CKD stages.
Materials and Methods
The German CAD-REF-registry is a nationwide multicenter prospective observational registry
of patients with at least one documented coronary artery stenosis50% in a major coronary
vessel and different degrees of CKD. Between January 2008 and May 2011, 3,352 patients were
enrolled at 32 recruiting cardiological centers located all over Germany. Recruiting centers
were hospitals with a department of cardiology, or internal medicine with cardiological focus,
as well as cardiologists in private practices performing coronary angiographies. Patients were
followed up for at least 24 month using standardized validated questionnaires. The detailed
trial design has been reported elsewhere [21].
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An approval was obtained from the Ethic Committee of the LandesärztekammerWestfalen-
Lippe and the Medical Faculty of theWestfälische Wilhelms-University Muenster (date August
16, 2007; No 2007-315-f-S). The study was conducted in accordance with the Declaration of Hel-
sinki. In December 2007 the contract research organization was instructed to register the proto-
col of the CAD-REF registry at ClinicalTrials.gov. Accidentally the registration was delayed until
May 2008. The identifier number is NCT00679419 (http://clinicaltrials.gov/). The authors con-
firm that all ongoing and related trials for this drug/intervention are registered.
Inclusion criteria, exclusion criteria and recruitment
In brief, patients were included if they were18 years, of Western European descent (Western
European parents and grandparents) and gave written informed consent. All had undergone a
current diagnostic coronary angiography documenting at least one stenosis50% in at least
one major coronary vessel (main stem, ramus circumflexus [LCX], left anterior descending
coronary artery [LAD], right coronary artery [RCA]).
Patients were included only once in the registry. Patients with organ transplantations other
than kidney transplantation, with immunosuppressive therapy apart from immunosuppressive
therapy after kidney transplantation, with polycystic renal disease, with known malignant
tumors as well as pregnant or breastfeeding patients were excluded from the registry.
Renal function
Serum creatinine (Scr) values were based on the method by Jaffé. To estimate the GFR, the
CKD-EPI formula was used [22,23]:
female patients:
Scr  0:7 mg=dl eGFR ðml=min=1:73 m2Þ ¼ 144 ðScr=0:7Þ0:329  ð0:993Þage=years
Scr > 0:7 mg=dl eGFR ðml=min=1:73 m2Þ ¼ 144 ðScr=0:7Þ1:209  ð0:993Þage=years
male patients:
Scr  0:9 mg=dl eGFR ðml=min=1:73 m2Þ ¼ 141 ðScr=0:9Þ0:411  ð0:993Þage=years
Scr > 0:9 mg=dl eGFR ðml=min=1:73 m2Þ ¼ 141 ðScr=0:9Þ1:209  ð0:993Þage=years
Based on the results of the eGFR and the dipstick test on proteinuria, patients were classified
into 5 CKD categories in accordance to the classification of the National Kidney Foundation
[16] as follows: category 1: eGFR90 ml/min/1.73 m² and proteinuria; category 2: eGFR 60–
89 ml/min/1.73 m²; category 3: eGFR 30–59 ml/min/1.73 m²; category 4: eGFR 15–29 ml/min/
1.73 m²; category 5: eGFR<15 ml/min/1.73 m². Patients on dialysis were also assigned to cate-
gory 5 regardless of their eGFR. Dipstick test on proteinuria was missing in 10 patients with no
residual urine.
Patients with eGFR90 ml/min/1.73 m² and a negative dipstick test were classified as con-
trol patients.
Study data collection
Data collection was performed by the IKKF Institute, Munich, Germany. Primary route of data
entry was via online electronic case forms. All information was kept confidential and transmit-
ted data was pseudonymized.
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At baseline visit, demographic characteristics, anthropometric data, medical history, and
ECG parameters were recorded. Initial data collection comprised a precisely characterized cor-
onary angiography with the degree and localization of stenosis according to the Cardiology
Audit and Registration Data Standards (CARDS) [24], medication, and standard serum and
urine laboratory parameters. In the case of a coronary intervention, additional data concerning
cardiac status and events in accordance to CARDS, indication for percutaneous coronary inter-
vention (PCI), stent implantation, degree of stenosis, medication, contrast dye application,
renal status and complications after intervention were also recorded.
Data and statistical analysis
Standard descriptive statistical methods were used to describe baseline characteristics. Means
with SD were given for continuous variables, and frequency distribution with percentages was
used for categorical variables. Right-skewed variables, such as laboratory variables, were loga-
rithmic (ln) transformed. Their means and 95% CIs intervals are presented in original scale
after back-transformation. The Jonckheere-Terpstra-test (J-T-test) was applied to test for
trends of ordinal and continuous variables across ordered categories. The Kruskal-Wallis test
was applied for the comparison of nominal categories, with subsequent Mann-Whitney-U-
tests comparing each category to all others. Non-directional associations were studied by
Spearman correlation coefficients. To test the effects of CKD stage, visit and their interaction
on medicalization, a logistic regression model was fit with intercept and the fixed effects CKD
stage, visit and their interaction. CKD stage was treated as a categorical variable. A two-sided
p0.05 was considered statistically significant.
Results
Between January 2008 and May 2011, 3,352 patients who met the inclusion criteria were con-
secutively included into the registry without any preselection. Table 1 and S1 Fig show the
patients’ characteristics and distribution for the whole study population, and in detail for the 6
subgroups.
Patients’ age increased significantly with advanced renal impairment (p<0.001, Table 1).
The percentage of women increased from 15.3% in the control group to 40.2% in CKD stage 4,
and 36.1% in the CKD stage 5 group (p<0.001). Patients with proteinuria increased from
15.6% in CKD stage 2 to 69.2% in CKD stage 5 (p<0.001). The proportions of patients with
traditional cardiovascular risk factors such as dyslipidemia (p = 0.08) and family history of
CAD (p<0.001) decreased with progressive renal dysfunction, whereas diabetes mellitus and
arterial hypertension were significantly more prevalent in patients with CKD stages 3 to 5 than
in patients with mild renal impairment (both p<0.001).
Valvular heart disease was two to five times more often in patients with CKD stages 3, 4 and
5 than in the control group and in CKD stage 1 group (p<0.001, Table 1). There was no signifi-
cant difference concerning mitral valve insufficiency, mitral valve stenosis, or aortic valve
insufficiency between the CKD groups (data not shown) whereas significantly more patients
with CKD 3–5 suffered from aortic valve stenosis compared to controls and patients with mild
renal impairment (p = 0.003).
The percentage of patients with a history of previous stroke (p<0.001), previous MI
(p = 0.02), previous coronary artery bypass grafting (CABG, p<0.001), previous PCI
(p = 0.006), previous valve replacement (p<0.001), and implanted pacemaker (p<0.001) was
significantly diverse between the different patient groups, with a trend to higher incidences
among patients with progressive renal failure (Table 1).
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Table 1. Patient characteristics at the time of enrollment.
Overall
population
Controls (eGFR
90 ml/min/
1.73 m²), no
proteinuria
CKD stage 1
(eGFR 90 ml/
min/1.73 m²),
proteinuria
CKD stage 2
(eGFR 60–89
ml/min/1.73
m²)
CKD stage 3
(eGFR 30–59
ml/min/1.73
m²)
CKD stage 4
(eGFR 15–29
ml/min/1.73
m²)
CKD stage 5
(eGFR <15 ml/
min/1.73 m²) or
dialysis
p
Patients, n (% of
all)
3,352
(100.0)
629 (18.8) 127 (3.8) 1,599 (47.7) 854 (25.5) 107 (3.2) 36 (1.1)
Women, n (%) 773 (23.1) 96 (15.3) 27 (21.3) 348 (21.8) 246 (28.8) 43 (40.2) 13 (36.1) <0.001
Age,
mean ± SD,
years
67.1 ± 10.4 57.1 ± 8.6 58.5 ± 9.7 67.8 ± 9.1 73.2 ± 7.7 75.0 ± 8.5 72.3 ± 7.9 <0.001
Height,
mean ± SD, cm
172.5 ± 8.6 174.9 ± 8.3 173.8 ± 8.0 172.9 ± 8.5 170.4 ± 8.4 168.8 ± 9.0 169.4 ± 9.1 <0.001
Weight,
mean ± SD, kg
84.2 ± 15.1 86.0 ± 15.6 86.1 ± 15.8 84.3 ± 14.9 83.0 ± 14.8 82.2 ± 16.8 80.3 ± 11.5 <0.001
Proteinuria, n
(%)
637 (19.1) 0 (0.0) 127 (100.0) 249 (15.6) 205 (24.0) 38 (35.5) 18 (69.2) <0.001
Dyslipidemia, n
(%)
2,178 (67.8) 420 (70.0) 77 (65.3) 1,048 (68.4) 546 (66.3) 66 (64.1) 21 (58.3) 0.08
Diabetes, n (%)
a)
1,076 (32.1) 135 (21.5) 35 (27.6) 480 (30.0) 350 (41.0) 57 (53.8) 19 (52.8) <0.001
Insulin-
dependent, n
(%) b)
427 (12.7) 47 (7.5) 15 (11.8) 155 (9.7) 156 (18.3) 37 (34.9) 17 (47.2) <0.001
Tobacco use:
ever smokers, n
(%)
1,769 (54.3) 448 (72.5) 84 (68.3) 796 (51.5) 383 (46.1) 46 (44.2) 12 (34.3) <0.001
Alcohol
consumption, n
(%)
1,611 (59.0) 355 (65.7) 82 (72.6) 787 (60.6) 349 (51.4) 29 (39.2) 9 (32.1) <0.001
PAOD, n (%) 350 (10.5) 31 (4.9) 12 (9.4) 143 (9.0) 121 (14.2) 29 (27.4) 14 (40.0) <0.001
Family history
CHD, n (%)
1,176 (42.5) 263 (50.6) 61 (56.0) 566 (43.7) 252 (34.4) 28 (32.2) 6 (26.1) <0.001
Arterial
hypertension, n
(%)
2,794 (83.4) 450 (71.5) 99 (78.0) 1,329 (83.2) 781 (91.5) 102 (95.3) 33 (91.7) <0.001
Pulse pressure,
mean ± SD,
mmHg
57.6 ± 16.4 54.0 ± 14.5 56.1 ± 15.4 58.9 ± 16.5 58.1 ±16.9 58.7 ± 18.0 57.7 ± 19.6 <0.001
Left ventricular
hypertrophy*, n
(%)
95 (2.9) 19 (3.0) 13 (10.3) 34 (2.1) 21 (2.5) 6 (5.8) 2 (5.7) 0.46
Valvular heart
disease, n (%)
454 (13.5) 32 (5.1) 13 (10.2) 201 (12.6) 172 (20.1) 27 (25.2) 9 (25.0) <0.001
Aortic valve
stenosis, n (%)
185 (41.1) 8 (25.0) 5 (38.5) 72 (36.2) 82 (48.2) 16 (59.3) 2 (22.2) 0.003
Previous stroke,
n (%)
188 (5.6) 20 (3.2) 5 (3.9) 86 (5.4) 66 (7.7) 6 (5.7) 5 (13.9) <0.001
Previous MI, n
(%)
1,086 (32.5) 214 (34.0) 26 (20.5) 484 (30.4) 299 (35.0) 49 (45.8) 14 (38.9) 0.02
Previous CABG,
n (%)
682 (20.3) 78 (12.4) 12 (9.4) 299 (18.7) 248 (29.0) 34 (31.8) 11 (30.6) <0.001
Previous PCI, n
(%)
1,494 (44.6) 271 (43.2) 33 (26.0) 717 (44.8) 402 (47.1) 57 (53.3) 14 (40.0) 0.006
Previous valve
replacement, n
(%)
48 (1.4) 4 (0.6) 1 (0.8) 18 (1.1) 16 (1.9) 5 (4.7) 4 (11.1) <0.001
(Continued)
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Table 2 shows the basic laboratory parameters and reveals highly significant differences
between the CKD subgroups (p<0.001). Spearman rank correlations are given in S1 Table
demonstrating that the albumin/creatinine ratio as well as the protein/creatinine ratio were sig-
nificantly positively associated with left ventricular ejection fraction (LVEF, p<0.001 and
p = 0.003, respectively). The albumin/creatinine ratio was also significantly positively related to
LVEF (when categorized as>40% and40%, p = 0.001, S1 Table).
Interventional parameters
In 16.4% to 42.5% of all coronary angiographies these were performed as emergency interven-
tions due to an acute coronary syndrome (Table 3). In patients with CKD stage 1 the rate of
emergency interventions was almost twice as high (42.5%; p<0.001, Table 3) compared to the
Table 1. (Continued)
Overall
population
Controls (eGFR
90 ml/min/
1.73 m²), no
proteinuria
CKD stage 1
(eGFR 90 ml/
min/1.73 m²),
proteinuria
CKD stage 2
(eGFR 60–89
ml/min/1.73
m²)
CKD stage 3
(eGFR 30–59
ml/min/1.73
m²)
CKD stage 4
(eGFR 15–29
ml/min/1.73
m²)
CKD stage 5
(eGFR <15 ml/
min/1.73 m²) or
dialysis
p
Pacemaker, n
(%)
232 (6.9) 13 (2.1) 5 (3.9) 81 (5.1) 112 (13.2) 18 (16.8) 3 (8.3) <0.001
BMI, body mass index; CABG, coronary artery bypass graft; CHD, coronary heart disease; CKD, chronic kidney disease; eGFR, estimated glomerular
ﬁltration rate; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PAOD, peripheral artery occlusive
disease; SD, standard deviation.
* determined by presence of a positive Sokolow Lyon index in the ECG.
a) Categories testet in J-T-test: non-diabetic patients (0) vs diabetic patients on dietetic (1), oral antidiabetic (2) or insulin (3) therapy.
b) Categories testet in J-T-test: patients receiving insulin therapy (3) vs patients on dietetic (1) or oral antidiabetic (2) therapy.
doi:10.1371/journal.pone.0148057.t001
Table 2. Laboratory parameters.
Overall
population
Controls (eGFR
90 ml/min/1.73
m²), no
proteinuria
CKD stage 1
(eGFR 90 ml/
min/1.73 m²),
proteinuria
CKD stage 2
(eGFR 60–89
ml/min/1.73
m²)
CKD stage 3
(eGFR 30–59
ml/min/1.73
m²)
CKD stage 4
(eGFR 15–29
ml/min/1.73
m²)
CKD stage 5
(eGFR <15 ml/
min/1.73 m²) or
dialysis
p
Patients, n (% of
all)
3,352
(100.0)
629 (18.8) 127 (3.8) 1,599 (47.7) 854 (25.5) 107 (3.2) 36 (1.1)
Creatinine, mean
(95%CI), mg/dl
1.0 (1.0–1.0) 0.8 (0.8–0.8) 0.8 (0.8–0.8) 0.9 (0.9–0.9) 1.2 (1.2–1.2) 1.9 (1.8–2.0) 4.7 (3.9–5.6) <0.001
eGFR 71.5 (70.8–
72.3)
99.0 (98.5–99.5) 99.3 (98.1–100.5) 75.5 (75.1–
75.9)
48.0 (47.4–
48.5)
25.1 (24.3–
25.9)
12.1 (9.8–14.3) <0.001
Urea, mean
(95%CI), mg/dl
21.7 (21.5–
22.0)
17.8 (17.4–18.2) 19.4 (18.5–20.3) 20.1 (19.8–
20.3)
26.5 (25.9–
27.1)
41.3 (38.8–
44.1)
49.9 (44.8–
55.5)
<0.001
Albumin/
creatinine, mean
(95%CI), mg/g
33.8 (31.5–
36.3)
18.5 (15.8–21.7) 25.0 (19.2–32.6) 26.4 (24.1–
29.0)
50.5 (44.5–
57.4)
121.9 (81.8–
181.7)
277.6 (139.5–
552.4)
<0.001
Protein/
creatinine, mean
(95%CI), mg/g
130.4
(126.7–
134.2)
106.3 (100.7–
112.1)
124.9 (108.4–
144.0)
115.5 (111.3–
119.9)
162.8 (153.8–
172.4)
305.8 (241.4–
387.5)
840.2 (497.9–
1,417.9)
<0.001
Cholesterol,
mean (95%CI),
mg/dl
173.6
(172.1–
175.1)
179.4 (176.2–
182.7)
190.2 (181.7–
199.1)
174.2 (172.1–
176.4)
167.4 (164.4–
170.4)
165.4 (156.0–
175.4)
166.9 (154.2–
180.7)
<0.001
eGFR indicates estimated glomerular ﬁltration rate.
doi:10.1371/journal.pone.0148057.t002
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average rate (21.3%). Additionally, patients with decreasing renal function suffered more often
from coronary three vessel artery disease (p<0.001; Fig 1).
About two thirds of the patients with CKD stage 4 suffered from NYHA class II, III or IV
(Table 3). Comparing patients with eGFR60 ml/min/1.73 m2 and with patients with eGFR
<60 ml/min/1.73 m2, the number of patients with decreased renal function (CKD stage 3–5)
Table 3. Cardiological and angiographical data.
Overall
population
Controls (eGFR
90 ml/min/1.73
m²), no
proteinuria
CKD stage 1
(eGFR 90 ml/
min/1.73 m²),
proteinuria
CKD stage 2
(eGFR 60–
89 ml/min/
1.73 m²)
CKD stage 3
(eGFR 30–
59 ml/min/
1.73 m²)
CKD stage 4
(eGFR 15–
29 ml/min/
1.73 m²)
CKD stage 5
(eGFR <15 ml/
min/1.73 m²)
or dialysis
p
Patients, n (% of
all)
3,352
(100.0)
629 (18.8) 127 (3.8) 1,599 (47.7) 854 (25.5) 107 (3.2) 36 (1.1)
Emergency
angiography, n (%)
714 (21.3) 169 (26.9) 54 (42.5) 322 (20.1) 140 (16.4) 22 (20.6) 7 (19.4) <0.001
Heart failure—
none, n (%)
1,739 (55.9) 382 (67.0) 78 (67.8) 884 (59.7) 353 (43.6) 25 (24.8) 17 (47.2) <0.001
NYHA I, n (%) 205 (6.6) 44 (7.7) 4 (3.5) 99 (6.7) 48 (5.9) 8 (7.9) 2 (5.6)
NYHA II, n (%) 657 (21.1) 104 (18.2) 23 (20.0) 304 (20.5) 196 (24.2) 22 (21.8) 8 (22.2)
NYHA III, n (%) 460 (14.8) 37 (6.5) 8 (7.0) 180 (12.2) 188 (23.2) 39 (38.6) 8 (22.2)
NYHA IV, n (%) 52 (1.7) 3 (0.5) 2 (1.7) 14 (0.9) 25 (3.1) 7 (6.9) 1 (2.8)
Coronary artery
disease, n (%)
3,352 <0.001
one vessel
disease
858 (25.6) 197 (31.3) 45 (35.4) 384 (24.0) 208 (24.4) 16 (15.0) 8 (22.2)
two vessel
disease
1,060 (31.6) 216 (34.3) 42 (33.1) 520 (32.5) 243 (28.5) 26 (24.3) 13 (36.1)
three vessel
disease
1,408 (42.0) 213 (33.9) 40 (31.5) 679 (42.5) 398 (46.6) 64 (59.8) 14 (38.9)
main stem 26 (0.8) 3 (0.5) 0 (0.0) 16 (1.0) 5 (0.6) 1 (0.9) 1 (2.8)
LVEF, n (%) 3,274 <0.001
Normal (>50%) 1,712 (52.3) 362 (58.7) 71 (55.9) 851 (54.7) 378 (45.4) 40 (37.7) 10 (27.8)
Slightly reduced
(41–50%)
621 (19.0) 118 (19.1) 15 (11.8) 298 (19.2) 167 (20.0) 15 (14.2) 8 (22.2)
Moderately
reduced (31–40%)
169 (5.2) 23 (3.7) 6 (4.7) 73 (4.7) 58 (7.0) 5 (4.7) 4 (11.1)
Severely
reduced (30%)
225 (6.9) 17 (2.8) 6 (4.7) 94 (6.0) 89 (10.7) 17 (16.0) 2 (5.6)
PCI performed, n
(%)
2,281 (68.0) 486 (77.3) 108 (85.0) 1,093 (68.4) 514 (60.2) 56 (52.3) 24 (66.7) <0.001
Intervened arteries
(LAD, LCX, RCA)
1,984 (59.2) 434 (69.0) 99 (78.0) 950 (59.4) 434 (50.8) 48 (44.9) 19 (52.8) 0.18
One, n (%) 1,788 (90.1) 397 (91.5) 91 (91.9) 853 (89.8) 389 (89.6) 41 (85.4) 17 (89.5)
Two, n (%) 177 (8.9) 34 (7.8) 8 (98.1) 88 (9.3) 39 (9.0) 6 (12.5) 2 (10.5)
Three, n (%) 19 (1.0) 3 (0.7) 0 (0.0) 9 (0.9) 6 (1.4) 1 (2.1) 0 (0.0)
Performed
stenting, n (%)
1,984 434 (92.7) 99 (95.2) 950 (91.3) 434 (90.4) 48 (88.9) 19 (90.5) 0.09
CABG
recommended, n
(%)
344 (10.3) 50 (7.9) 10 (7.9) 174 (10.9) 91 (10.7) 15 (14.0) 4 (11.1) 0.04
CABG, coronary artery bypass graft; CAD, coronary artery disease; CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; LAD, left
artery descending; LVEF, left ventricular ejection fraction; LCX, left circumﬂex artery; PCI, percutaneous coronary intervention; RCA, right coronary artery;
SD, standard deviation.
doi:10.1371/journal.pone.0148057.t003
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and NYHA class II, III, and IV was 1.2-fold, 2.4-fold and 4.1-fold that of patients with mildly
reduced (CKD 1–2) or normal renal function (controls; Table 3).
CAD patients without (= controls) or mild renal impairment (= CKD stage 1) underwent a
PCI more often than patients with moderate to severe renal impairment (p<0.001). In contrast,
recommendations for CABG almost doubled in CKD stage 4 compared to the control group
(p = 0.04; Table 3).
Medication at enrollment and at discharge
There were marked changes regarding the medication between the time of enrollment (S2
Table) and discharge (S3 Table) depending on patients’ CKD stage. Fig 2 displays these differ-
ences between enrollment and discharge, as well as between the distinct CKD stages with
regard to four standard drug classes in CAD (beta-blocker, angiotensin converting enzyme
(ACE) inhibitors and/or angiotensin II type 1 receptor blockers (ARBs), anticoagulants, stat-
ins). Results of the corresponding logistic regression analyses are displayed in S4 Table. In sum-
mary, with regard to all four drug classes a significant increase in prescriptions between
enrollment and discharge could be observed, as well as lower prescription rates of beta-blockers
and ACE inhibitors/ARBs with increasing CKD stages. However, regarding all patients (Fig 2),
significant interactions between CKD groups and visits were observed indicating that the prob-
ability for prescribing a distinct medication at a particular visit is associated with CKD stage.
In contrast, in the subgroup of patients with moderately to severely reduced LVEF the pre-
scription frequency of beta-blockers and ACE inhibitors/ARBs was higher in patients with end-
stage renal disease as compared to the total cohort (Fig 3).
In-hospital outcome
Five patients (0.1%) required dialysis after coronary intervention, 4 (11.1%) of them had been
initially classified as patients in CKD stage 5. During or after intervention 7 (0.2%) patients
Fig 1. Proportions of patients with different degrees of CAD according to their renal function. P-values form Jonckheere-Terpstra tests.
doi:10.1371/journal.pone.0148057.g001
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suffered from newMI, and 5 patients (0.1%) suffered from stroke (Table 4). A recurrent PCI
was necessary in 124 patients (3.7%); none of them was in the CKD stage 5 group. After coro-
nary angiography, 98 patients (2.9%) underwent CABG, none of them in the CKD stage 5
group.
A total of 3,037 (90.6%) patients were discharged alive, 263 (7.9%) were transferred to
another hospital, and 42 (1.3%) were discharged to medical rehabilitation measures (Table 4).
Eight (0.2%) patients died during hospital stay with a continuously increasing mortality in
patients with progressive renal impairment (Table 4, Fig 4).
Discussion
The CAD-REF registry is a German-wide prospective observational multicenter registry. It
aims at evaluating the characteristics and outcome of patients with angiographically docu-
mented CAD, with and without concomitant CKD to identify new risk factors and biomarkers
for patients’ prognosis. Another important issue is the evaluation of current invasive treatment
patterns and prescription rates of guideline-recommended standard medication.
Until now, only few prospective observational studies exist that evaluate treatment, outcome
and factors contributing to the progression of CKD [18–20,25]. Of these, only CAD-REF and
APPROACH [25] included a control group with preserved renal function. Moreover, only the
CAD-REF registry assessed the coronary status determined by coronary angiography in detail
(classification based on CARDS [24]).
In the CAD-REF registry, we found that with advanced renal impairment known cardiovas-
cular risk factors such as hypertension and diabetes mellitus were significantly more frequent.
Many other comorbidities, such as previous MI and CABG, valve replacement and advanced
stages of congestive heart failure were also increased with advanced renal failure. Our findings
are in line with other studies demonstrating the prominent cardiovascular morbidity and mor-
tality of CKD patients [4–6,8,15,26, 27]. Moreover, based on our detailed angiographic evalua-
tion we were able to show that the clinical severity of CAD strongly depended on residual
eGFR and thus patients’ CKD stages, with a higher number of diseased coronary vessels (Fig 1)
and a lower LVEF with declining eGFRs (Table 3). Two other studies also described an increase
in severity of CAD with impaired renal function, although both studies were based on a case
control design of non-CKD and CKD patients with eGFR above or below 60 ml/min/1.73 m2
[28,29].
Furthermore, we found highly significant correlations between angiographic parameters
and the urinary albumin/creatinine and protein/creatinine ratio (S1 Table). Our results point
to the fact that proteinuria in combination with other risk scores (FRAMINGHAM; PRO-
CAM) may enhance the sensitivity and specificity for predicting the outcome of patients with
and without known CAD. The planned follow-up analyses in CAD-REF will show whether
and to what extent the combination of the clinical, angiographic and laboratory parameters
will help to identify different risk groups and identify patients at high cardiovascular risk.
Differences in in-hospital treatment
At the time of enrollment a relatively low number of CAD-REF patients were treated with car-
dioprotective drugs such as ACE inhibitors or ARBs, beta-blockers, statins and platelet inhibi-
tors as also found in other reports [14,15,27,30,31,]. From enrollment to discharge, these
Fig 2. Proportion of patients (complete cohort) with respective medication prescription by CKD stage
and visit (enrollment at hospital versus hospital discharge). Effects of CKD stage, visit and CKD stage x
visit-interactions were tested via logistic regression.
doi:10.1371/journal.pone.0148057.g002
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treatments increased markedly in patients with CKD stage 1 to 3, but no comparable increase
was observed in stage 4 and 5; the latter received especially ACE inhibitors and ARBs but also
beta-blockers and statins significantly less frequently (Fig 2). This finding is remarkable since
ACE inhibitors and ARBs not only belong to the standard therapy for hypertension and CAD,
but are also known to slow down kidney disease progression and to improve proteinuria in dia-
betic nephropathy [16,32]. Therefore, current guidelines give clear recommendations in favor
of these drugs even in higher CKD stages [16,33].
Medical undertreatment, known as “therapeutic nihilism” in patients with CAD and CKD
has been reported previously in other cardiological settings [14,15,27]. This observation might
partly be explained by cardiologists’ concerns to induce further kidney deterioration by these
drugs. In contrast, in cohorts mainly treated by nephrologists [30,34,35] the use of ACE inhibi-
tors, ARBs and loop diuretics was markedly higher than in our registry, and moreover further
increased with higher CKD stages. Vice versa, the use of beta-blockers was 2 to 3 times higher
in our series compared to the nephrological studies [30,34,35] demonstrating that cardiologists
still have a favor for these substances.
Interestingly, in CAD-REF patients with a LVEF40% the prescription of beta-blockers,
ACE inhibitors and ARBs, and loop diuretics was higher in all CKD stages including stage 4
and 5 (Fig 3) compared to the whole cohort, which may indicate that cardiologists ranked the
treatment of heart failure above potential harms on kidney function.
Fig 3. Proportion of patients (subgroup with moderately to severely reduced LVEF, LVEF40%) with
respective medication prescription by CKD stage and visit (enrollment at hospital versus hospital
discharge). Effects of CKD stage, visit and CKD stage x visit-interactions were tested via logistic regression.
doi:10.1371/journal.pone.0148057.g003
Table 4. In-hospital treatment and outcome.
Overall
population
Controls (eGFR
90 ml/min/1.73
m²), no
proteinuria
CKD stage 1
(eGFR 90 ml/
min/1.73 m²),
proteinuria
CKD stage 2
(eGFR 60–89
ml/min/1.73
m²)
CKD stage 3
(eGFR 30–59
ml/min/1.73
m²)
CKD stage 4
(eGFR 15–29
ml/min/1.73
m²)
CKD stage 5
(eGFR <15 ml/
min/1.73 m²) or
dialysis
pa)
Patients, n (% of
all)
3,352
(100.0)
629 (18.8) 127 (3.8) 1,599 (47.7) 854 (25.5) 107 (3.2) 36 (1.1)
CABG, n (%) 98 (2.9) 14 (2.2) 5 (3.9) 47 (2.9) 26 (3.0) 6 (5.7) 0 (0.0) 0.32
MI after
angiography, n (%)
7 (0.2) 4 (0.6) 0 (0.0) 2 (0.1) 0 (0.0) 0 (0.0) 1 (2.8) 0.09
Re-PCI, n (%) 124 (3.7) 27 (4.3) 3 (2.4) 66 (4.1) 26 (3.0) 2 (1.9) 0 (0.0) 0.11
Stroke, n (%) 5 (0.1) 2 (0.3) 0 (0.0) 3 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0.13
Discharge status 0.03
Discharged to
home, n (%)
3,037 (90.7) 581 (92.5) 113 (89.0) 1,448 (90.6) 777 (91.0) 86 (80.4) 32 (88.9) 0.06
In-hospital death,
n (%)
8 (0.2) 0 (0.0) 0 (0.0) 3 (0.2) 3 (0.4) 1 (0.9) 1 (2.8) 0.02
Discharged to
another hospital, n
(%)
263 (7.9) 42 (6.7) 7 (5.5) 129 (8.1) 66 (7.7) 17 (15.9) 2 (5.6) 0.09
Discharge to
rehabilitation
measures, n (%)
42 (1.3) 5 (0.8) 7 (5.5) 18 (1.1) 8 (0.9) 3 (2.8) 1 (2.8) 0.92
CABG, coronary artery bypass graft; CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; MI, myocardial infarction; PCI,
percutaneous coronary intervention.
a) p-values for variables CABG, MI after angiography, Re-PCI and stroke are from J-T-tests; p-values for discharge status result from a Kruskal-Wallis-test
followed by category-wise Mann-Whitney-U-tests.
doi:10.1371/journal.pone.0148057.t004
CAD-REF Baseline Characteristics and Prescription Patterns
PLOS ONE | DOI:10.1371/journal.pone.0148057 February 9, 2016 12 / 16
Therefore, more effort is needed to promote the current KDIGO guidelines to other disci-
plines beside nephrology to underline that ACE inhibitors and ARBs are also nephroprotective
in all stages of CKD.
In patients with severe heart failure (NYHA class III-IV), also aldosterone receptor antago-
nists (MR antagonists) are recommended. The ACCF/AHA 2013 guidelines [36] also recom-
mend the use of MR antagonists in patients with NYHA class II and LVEF35% who have a
history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels, and
postmyocardial infarction patients with LVEF40% who develop heart failure symptoms or
have a history of diabetes mellitus (ACCF/AHA). However, in our study only 7.0% of the over-
all study population was treated with a MR antagonist (spironolactone or eplerenone) while
9.3% of the CKD stage 4 patients and 2.8% of the CKD stage 5 patients received this medica-
tion. This is of relevance as dosing of spironolactone has to be adapted accordingly in patients
with heart failure and concomitant renal impairment and is explicitly not recommended in
patients with an eGFR<30 ml/minute/1.73 m2 (ACCF/AHA) [36].
Limitations and conclusion
Our data derived from an observational registry and not from a randomized study and allow
therefore no conclusions about causal interactions. However, our data reflect the current treat-
ment patterns in an industrialized nation in which all inhabitants are insured by law and all
health expenses are reimbursed which, therefore, cannot represent a reason for low prescrip-
tions of drugs.
The number of patients in CKD stage 4 and 5 was rather small with only 143 patients. This
weakens statements for this subgroup. Due to the “real world design” of the study with
Fig 4. Proportion of patients who died in-hospital according to their renal function. P-value fromMann-Whitney-U-test testing category “In-hospital
death” vs all other categories of variable “discharge status”.
doi:10.1371/journal.pone.0148057.g004
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consecutive recruitment without patients’ preselection the composition of the study cohort
illustrates a representative sample of the German population with CAD and concomitant
CKD.
In summary, CAD patients with decreasing renal function not only suffer from more
comorbidities but also receive standard treatment still less often in contrast to current guideline
recommendations. Since CKD advances to a global health problem, and cardiologists and
nephrologists have different treatment concepts for the same patients at risk, more consequent
and in part more common treatment strategies and a broader knowledge of them appear to be
recommended to meet the challenges of this disease burden.
Supporting Information
S1 Fig. Distribution of patients in the CAD-REF registry according to CKD stage.
(TIF)
S1 File. Definition of cardiovascular risk factors.
(PDF)
S1 Table. Spearman rank correlational analysis of laboratory parameters and coronary
artery disease, multivessel disease, LVEF and LVEF40%.
(PDF)
S2 Table. Medication at time of enrollment before coronary angiography.
(PDF)
S3 Table. Medication at hospital discharge after coronary angiography.
(PDF)
S4 Table. Logistic regression for effects of CKD group, visits and interaction with regard to
medication in the complete CAD-REF cohort.
(PDF)
Acknowledgments
The authors gratefully acknowledge the willingness and patience of all patients for participating
in the registry and the follow-ups. We are also indebted to the enthusiastic and unlimited sup-
port of all physicians and health care staff at the recruiting centers.
Without the technical support of the IKKF GmbH in Munich regarding data management
and all concerns of registry performance, CAD-REF would not have been possible. Finally, we
thank our local study nurses Mrss. Jutta Beilker and Anke Schneider-Schwinning and our local
technician Ms. Mira Schiwek for their excellent contribution to this registry.
Author Contributions
Analyzed the data: HOP KW. Wrote the paper: HR GB CE EB. Conception and design of the
CAD-REF registry: EB GB HP HR RES. Collection and assembly of data: EB GB HP HR RES.
Analysis of human material: MF. Analysis, interpretation and critical revision: HR GB CE RES
MF HOP BS PB KWHP EB.
References
1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a
global public health problem: approaches and initiatives—a position statement from Kidney Disease
Improving Global Outcomes. Kidney Int. 2007; 72:247–259. PMID: 17568785
CAD-REF Baseline Characteristics and Prescription Patterns
PLOS ONE | DOI:10.1371/journal.pone.0148057 February 9, 2016 14 / 16
2. Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, et al. Evolving importance of kid-
ney disease: from subspecialty to global health burden. Lancet. 2013; 382:158–169. doi: 10.1016/
S0140-6736(13)60439-0 PMID: 23727165
3. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk
factor for development of cardiovascular disease: a statement from the American Heart Association
Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology,
and Epidemiology and Prevention. Circulation. 2003; 108:2154–2169. PMID: 14581387
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death,
cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296–1305. PMID: 15385656
5. Bello AK, Hemmelgarn B, Lloyd A, JamesMT, Manns BJ, Klarenbach S, et al. Associations among esti-
mated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. Clin J Am Soc
Nephrol. 2011; 6:1418–1426. doi: 10.2215/CJN.09741110 PMID: 21527648
6. Reinecke H, Trey T, Matzkies F, Fobker M, Breithardt G, Schaefer RM. Grade of chronic renal failure,
and acute and long-term outcome after percutaneous coronary interventions. Kidney Int. 2003;
63:696–701. PMID: 12631136
7. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between
renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;
351:1285–1295. PMID: 15385655
8. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association
among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and cor-
onary artery disease. J Am Coll Cardiol. 2004; 44:1587–1592. PMID: 15489090
9. Reinecke H, Brand E, Mesters R, Schäbitz WR, Fisher M, Pavenstädt H, et al. Dilemmas in the man-
agement of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol. 2009; 20:705–711. doi: 10.
1681/ASN.2007111207 PMID: 19092127
10. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, et al. Cardiovascular disease in
chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).
Kidney Int. 2011; 80:572–586. doi: 10.1038/ki.2011.223 PMID: 21750584
11. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation,
classification, and stratification. Am J Kidney Dis. 2002; 39: S1–S266. PMID: 11904577
12. Kidney Disease: Improving Global Outcomes (KDIGO) Blood PressureWork Group. KDIGO Clinical
Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int
Suppl. 2012; 2:337–414.
13. Ritz E. Minor renal dysfunction: An emerging independent cardiovascular risk factor. Heart. 2003;
89:963–964. PMID: 12922986
14. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor
therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol.
2003; 42:201–208. PMID: 12875751
15. Szummer K, Lundman P, Jacobson SH, Schön S, Lindbäck J, Stenestrand U, et al. Influence of renal
function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from
the SwedishWeb-System for Enhancement and Development of Evidence-Based Care in Heart Dis-
ease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009; 120:851–
858. doi: 10.1161/CIRCULATIONAHA.108.838169 PMID: 19704097
16. Kidney Disease: Improving Global Outcomes (KDIGO) CKDWork Group. KDIGO 2012 Clinical Prac-
tice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;
3:1–150.
17. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for
evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the ure-
mic puzzle? Clin J Am Soc Nephrol. 2008; 3:505–521. doi: 10.2215/CJN.03670807 PMID: 18184879
18. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, et al. The Chronic Renal Insuffi-
ciency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol. 2003; 14:S148–153. PMID:
12819321
19. Imai E, Matsuo S, Makino H, Watanabe T, Akizawa T, Nitta K, et al. Chronic Kidney Disease Japan
Cohort (CKD-JAC) study: design and methods. Hypertens Res. 2008; 31:1101–1107. doi: 10.1291/
hypres.31.1101 PMID: 18716357
20. Eckardt KU, Bärthlein B, Baid-Agrawal S, Beck A, Busch M, Eitner F, et al. The German Chronic Kidney
Disease (GCKD) study: design and methods. Nephrol Dial Transplant. 2012; 27:1454–1460. doi: 10.
1093/ndt/gfr456 PMID: 21862458
CAD-REF Baseline Characteristics and Prescription Patterns
PLOS ONE | DOI:10.1371/journal.pone.0148057 February 9, 2016 15 / 16
21. Brand E, Pavenstädt H, Schmieder RE, Engelbertz C, Fobker M, Pinnschmidt HO, et al. The Coronary
Artery Disease and Renal Failure (CAD-REF) registry: trial design, methods, and aims. Am Heart J.
2013; 166:449–456. doi: 10.1016/j.ahj.2013.06.010 PMID: 24016493
22. Zamora E, Lupón J, Vila J, Urrutia A, de Antonio M, Sanz H, et al. Estimated glomerular filtration rate
and prognosis in heart failure: value of the Modification of Diet in Renal Disease Study-4, chronic kidney
disease epidemiology collaboration, and cockroft-gault formulas. J Am Coll Cardiol. 2012; 59:1709–
1715. doi: 10.1016/j.jacc.2011.11.066 PMID: 22554602
23. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to esti-
mate glomerular filtration rate. Ann Intern Med. 2009; 150:604–612. PMID: 19414839
24. Flynn MR, Barrett C, Cosío FG, Gitt AK, Wallentin L, Kearney P, et al. The Cardiology Audit and Regis-
tration Data Standards (CARDS), European data standards for clinical cardiology practice. Eur Heart J.
2005; 26:308–313. PMID: 15618029
25. Ghali WA, Knudtson ML. Overview of the Alberta Provincial Project for Outcome Assessment in Coro-
nary Heart Disease. On behalf of the APPROACH investigators. Can J Cardiol. 2000; 16:1225–1230.
PMID: 11064296
26. Reinecke H, Nabauer M, Gerth A, Limbourg T, Treszl A, Engelbertz C, et al. Morbidity and treatment in
patients with atrial fibrillation and chronic kidney disease. Kidney Int. 2015; 87:200–209. doi: 10.1038/
ki.2014.195 PMID: 24897032
27. Kalra PR, García-Moll X, Zamorano J, Kalra PA, Fox KM, Ford I, et al. Impact of chronic kidney disease
on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272
patients. PLoS One. 2014; 9(7):e102335. doi: 10.1371/journal.pone.0102335 PMID: 25051258
28. Ding Z, Wang X, Chen Z, Zhang X, Tang C, Feng Y, et al. Chronic kidney disease predicts poor progno-
sis in patients with stable premature coronary artery disease. Eur J Intern Med. 2012; 23:716–719. doi:
10.1016/j.ejim.2012.07.003 PMID: 22857882
29. Kiyosue A, Hirata Y, Ando J, Fujita H, Morita T, Takahashi M, et al. Relationship between renal dysfunc-
tion and severity of coronary artery disease in Japanese patients. Circ J. 2010; 74:786–791. PMID:
20160394
30. Martínez-Castelao A, Górriz JL, Portolés JM, De Alvaro F, Cases A, Luño J, et al. Baseline characteris-
tics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational
cohort study. BMC Nephrol. 2011; 12:53. doi: 10.1186/1471-2369-12-53 PMID: 21970625
31. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, et al. Use of evidence-based thera-
pies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment eleva-
tion myocardial infarction in patients with chronic kidney disease: a report from the National
Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circula-
tion. 2010; 121:357–365. doi: 10.1161/CIRCULATIONAHA.109.865352 PMID: 20065168
32. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic
kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;
382:339–352. doi: 10.1016/S0140-6736(13)60595-4 PMID: 23727170
33. Dasari TW, Cohen DJ, Kleiman NS, Keyes MJ, Yen CH, Hanna EB, et al. Statin therapy in patients with
chronic kidney disease undergoing percutaneous coronary intervention (from the Evaluation of Drug
Eluting Stents and Ischemic Events Registry). Am J Cardiol. 2014; 113:621–625. doi: 10.1016/j.
amjcard.2013.11.006 PMID: 24342762
34. Imai E, Matsuo S, Makino H, Watanabe T, Akizawa T, Nitta K, et al. Chronic Kidney Disease Japan
Cohort study: baseline characteristics and factors associated with causative diseases and renal func-
tion. Clin Exp Nephrol. 2010; 14: 558–570. doi: 10.1007/s10157-010-0328-6 PMID: 20700621
35. Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Hypertension awareness, treat-
ment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC)
Study. Am J Kidney Dis. 2010; 55:441–451. doi: 10.1053/j.ajkd.2009.09.014 PMID: 19962808
36. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline
for the management of heart failure: a report of the American College of Cardiology Foundation/Ameri-
can Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62:e147–239 doi:
10.1016/j.jacc.2013.05.019 PMID: 23747642
CAD-REF Baseline Characteristics and Prescription Patterns
PLOS ONE | DOI:10.1371/journal.pone.0148057 February 9, 2016 16 / 16
